Overview

Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if pembrolizumab works for cervical adenocarcinoma treat with concurrent chemo-carbon-ion radiaotherapy (CIRT). The main questions it aims to answer are: Does concurrent chemo-CIRT with pembrolizumab improves 2-year progression-free survival (PFS), compared with concurrent chemoradiotherapy with conventional X-rays?

Phase:

PHASE2

Details

Lead Sponsor:

Gunma University

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

pembrolizumab